China nod to two Sanofi drugs for rare and complex conditions
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
The feature will be available across all Max Healthcare facilities, offering patients consistent and convenient access to services nationwide
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
Subscribe To Our Newsletter & Stay Updated